P1043 REAL-LIFE PERSISTENCE AND ADHERENCE IN ETV TREATED CHRONIC HEPATITIS B PATIENTS: RESULTS OF A GERMAN PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY

Abstract

P1043 REAL-LIFE PERSISTENCE AND ADHERENCE IN ETV TREATED CHRONIC HEPATITIS B PATIENTS: RESULTS OF A GERMAN PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY J. Petersen, T. Wilke, S. Mauss, R. Heyne, C. Herold, M. Wiese, K. Boeker, T. Pichl, D. Hueppe. ifi – Institut fur Interdisziplinare Medizin, Hamburg, IPAM Wismar, Wismar, Medizinisches Versorgungszentrum, Duesseldorf, Leberzentrum Checkpoint, Berlin, Internisten am Ring, Nuernberg, Gesellschaft fur Klinische Studien, Leipzig, Leberpraxis Hannover, Hannover, BristolMyers Squibb GmbH & Co. KGaA, Munich, Gastroenterologische Gemeinschaftspraxis Herne, Herne, Germany E-mail: petersen@ifi-medizin.de Background and Aims: Entecavir (ETV) is a very effective and safe treatment option in chronic hepatitis B (CHB) patients. However, some patients show only a partial virologic response. The most reasonable explanation is non-persistence/non-adherence. Persistence and adherence measurement is underrepresented in clinical trials. Therefore, the extent of non-persistence (NP), nonadherence (NA) and clinical outcomes of any NP/NA were measured in ETV-treated patients in a real-life study. Methods: In a prospective observational multicenter study, persistence and adherence were measured based on documented ETV prescriptions within a 12 month period. A patient was defined as NP if he missed all treatment doses in >30 subsequent days. Adherence was measured based on medication possession ratio (MPR) between first and last documented prescription (NA if MPR 30 subsequent days (NP group), 30% of patients in the NP group (n =9) and none of the persistent patients were classified as non-adherent. Mean MPR for all patients was 95.3%. 84.4% of persistent/adherent patients and 63.0% of patients in the NP group reached undetectable HBV-DNA levels (p = 0.022). So far no significantly correlating factors for NP/NA could be detected.